ACC CardiaCast

This episode is part of ACC's ongoing initiative on Implementing the 2026 Dyslipidemia Guidelines. Join Drs. Pam Morris and Roger Blumenthal as they explore updates to the Dyslipidemia Guidelines, the patient populations who benefit most, and how to make sense of all of this new information. They provide a practical, evidence‑based discussion designed to support better decision‑making in everyday care.  This podcast is part of the ACC's Implementing the 2026 Dyslipidemia Guidelines: From Risk Stratification to Personalized Treatment online course, supported by Merck & Co. and Eli Lilly and Company. Visit the online course to access additional educational activities on this topic.

This episode is part of ACC's ongoing initiative to review aortic stenosis care and its approach to screening and diagnosis. Drs. Wayne Batchelor and Sammy Elmariah review the barriers to aortic stenosis diagnosis. The conversation highlights symptom variability, sex-based and demographic differences, and screening gaps in the real-world practice.    This podcast is part of the ACC's Transforming Aortic Stenosis Care: An Optimal Approach to Screening & Diagnosis initiative, supported by an educational grant from Edwards Lifesciences.  

This episode is part of ACC's ongoing initiative on implementing the 2026 Dyslipidemia guidelines. Join Drs. Samuel Kim and Romit Bhattacharya as they review new therapeutic developments from the guidelines during this discussion on the intersections of dyslipidemia and cardiometabolic syndrome management.   This podcast is part of the ACC's Implementing the 2026 Dyslipidemia Guidelines: From Risk Stratification to Personalized Treatment initiative, supported by Merck & Co, and Eli Lilly and Company. 

This episode is part of ACC's ongoing initiative to recognize the risks and tackle management of hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG). Drs. Michael Miller and Archna Bajaj discuss the importance of correctly diagnosing sHTG, recognizing familial chylomicronemia syndrome (FCS), and following guideline‑based testing sequences.  This podcast is part of the ACC's Hypertriglyceridemia and Cardiovascular Health: Recognizing Risks and Tackling Management initiative, supported by Ionis Pharmaceuticals. 

In this CardiaCast episode, Kevin M. Alexander, MD is joined by Sarah Cuddy, MBBCh, to discuss the latest clinical data for investigational therapies and available treatments for transthyretin amyloid cardiomyopathy (ATTR-CM), as well as the potential implications of these findings on clinical practice and future clinical studies. First, they will explore results from CARDIO-TTRansform, the phase 3 trial of eplontersen in ATTR-CM, followed by the results from REVEAL, the phase 3 trial using radiotracer I-124 evuzamitide to detect cardiac amyloidosis. Next, they will discuss findings from ATTRibute-CM and its open-label extension on the survival benefits of acoramidis in variant ATTR-CM (ATTRv-CM) over 54 months. Lastly, they will cover recently published studies describing the extracardiac effects of available therapies for ATTR-CM, specifically those describing the effects of acoramidis on kidney function and the effects of vutrisiran on gastrointestinal events.   This activity is supported by an educational grant from BridgeBio and developed by Med-IQ in collaboration with the American College of Cardiology.